Group photo of five medical professionals discussing personalized therapy decisions in myelodysplastic syndromes.

Clinical Insights

08/07/2026

Ep. 4: Personalizing Therapy Decisions in Lower-Risk Myelodysplastic Syndromes

Hetty Carraway, MDRahul Gosain, MD, MBAYasmin Abaza, MDThomas LeBlanc, MD, MAAmer Zeidan, MBBS, MD
Three medical professionals discussing treatment options for late relapsed multiple myeloma, featuring Dr. Maximilian Merz, Dr. Rohit Gosain, and Dr. Rahul Gosain.

Uncategorized

08/06/2026

Treatment Options and Sequencing for Late Relapsed/Refractory Multiple Myeloma

Promotional image for OncUpdates featuring Dr. Shaji Kumar, Dr. Rohit Gosain, and Dr. Rahul Gosain discussing navigating first relapse in multiple myeloma.

Videos & Podcasts

08/06/2026

Navigating First Relapse in Multiple Myeloma

Group photo of four medical professionals, including Dr. Shaji Kumar, Dr. Vincent Rajkumar, Dr. Rahul Gosain, and Dr. Rohit Gosain, discussing findings from ENDURANCE trial for multiple myeloma.

08/05/2026

Findings From ENDURANCE Trial Offer New Standard of Care for Multiple Myeloma

Group photo of three doctors discussing CAR T-Cell Therapy in Multiple Myeloma, highlighting collaboration and adverse effects management.

Resource Centers

08/04/2026

CAR T-Cell Therapy in Multiple Myeloma: Managing Adverse Effects Through Collaboration

Conferences

View All
Panel of three medical professionals at EHA 2026 conference discussing leukemia and myelofibrosis presentations.

Conferences

08/03/2026

Key Leukemia and Myelofibrosis Presentations at EHA 2026

Eunice Wang, MDRahul Gosain, MD, MBARohit Gosain, MD
Group photo of three medical professionals discussing lymphoma presentations at EHA 2026.

Conferences

07/31/2026

4 Key Lymphoma Presentations From EHA 2026

Carla Casulo, MDRahul Gosain, MD, MBARohit Gosain, MD
Two doctors, Dr. Rahul Banerjee and Dr. Rohit Gosain, featured in a digital graphic about emerging data for CELMoDs in multiple myeloma.

Conferences

07/22/2026

The Emerging Data for CELMoDs in Multiple Myeloma

Rahul Banerjee, MD, FACPRohit Gosain, MD
Experts Dr. Rahul Gosain, Dr. Rohit Gosain, Dr. Brian Rini, and Dr. Thomas Powles discuss 6 clinical trials on treatment options for genitourinary cancers.

Conferences

07/15/2026

6 Trials Impacting Treatment Options for Genitourinary Cancers

Thomas Powles, MD, MBBS, MRCPBrian Rini, MD, FASCORahul Gosain, MD, MBARohit Gosain, MD
Group of three medical professionals, including Dr. Hope Rugo, discussing breast cancer updates from ASCO 2026.

Conferences

07/13/2026

7 Key Breast Cancer Updates From ASCO 2026

Hope Rugo, MD, FASCORahul Gosain, MD, MBARohit Gosain, MD
Dr. Rahul Banerjee, Dr. Rohit Gosain, and Dr. Rahul Gosain discuss key updates from EHA 2026 on multiple myeloma trials.

Conferences

07/07/2026

5 Key Multiple Myeloma Trial Updates From EHA 2026

Rohit Gosain, MDRahul Gosain, MD, MBARahul Banerjee, MD, FACP
Dr. Neena Vijayvergia, Dr. Rahul Gosain, and Dr. Rohit Gosain discussing key gastrointestinal trials at ASCO 2026 for clinical practice.

Conferences

07/02/2026

ASCO 2026: Key GI Trials Shaping Clinical Practice

Neena Vijayvergia, MDRahul Gosain, MD, MBARohit Gosain, MD
Dr. Joshua Brody, MD, in front of New York City skyline, discussing Liso-Cel treatment for relapsed DLBCL patients.

Conferences

07/02/2026

Liso-Cel in Relapsed DLBCL: Patient Selection, Outcomes, and Referral Strategies

Joshua Brody, MD

Clinical Insights

View All
Group photo of five medical professionals discussing personalized therapy decisions in myelodysplastic syndromes.

Clinical Insights

08/07/2026

Ep. 4: Personalizing Therapy Decisions in Lower-Risk Myelodysplastic Syndromes

Hetty Carraway, MDRahul Gosain, MD, MBAYasmin Abaza, MDThomas LeBlanc, MD, MAAmer Zeidan, MBBS, MD
Panel of five medical experts discussing managing imetelstat toxicities in lower-risk MDS during OncUpdates episode 3.

Clinical Insights

08/04/2026

Ep. 3: Managing Imetelstat Toxicities in Lower-Risk MDS

Hetty Carraway, MDRahul Gosain, MD, MBAYasmin Abaza, MDThomas LeBlanc, MD, MAAmer Zeidan, MBBS, MD
Panel of five medical experts discussing treatment sequencing in lower-risk MDS at OncUpdates.

Clinical Insights

08/01/2026

Ep. 2: Imetelstat, Luspatercept, and ESAs: Treatment Sequencing in Lower-Risk MDS

Hetty Carraway, MDRahul Gosain, MD, MBAYasmin Abaza, MDThomas LeBlanc, MD, MAAmer Zeidan, MBBS, MD
Medical professionals Dr. Raji Shameem, Dr. David H. Aggen, Dr. Alexandra Drakaki, and Dr. Ashish M. Kamat discuss personalized perioperative treatment for MIBC with NIAGARA and EV-based regimens.

Clinical Insights

07/31/2026

Ep. 4: Personalizing Perioperative Treatment for Muscle-Invasive Bladder Cancer With NIAGARA and EV-Based Regimens

Ashish M. Kamat, MD, MBBS, FACSDavid H. Aggen, MD, PhDAlexandra Drakaki, MD, PhDRaji Shameem, MD
Medical professionals discussing perioperative therapy for MIBC based on patient and tumor characteristics in a hospital setting.

Clinical Insights

07/30/2026

Ep. 3: Selecting Perioperative Therapy for Muscle-Invasive Bladder Cancer Based on Patient and Tumor Characteristics

Ashish M. Kamat, MD, MBBS, FACSDavid H. Aggen, MD, PhDAlexandra Drakaki, MD, PhDRaji Shameem, MD
Group photo of five medical professionals discussing next-generation sequencing and IPSS-M in lower-risk MDS for OncUpdates episode 1.

Clinical Insights

07/29/2026

Ep. 1: The Growing Role of Next-Generation Sequencing and IPSS-M in Lower-Risk MDS

Hetty Carraway, MDRahul Gosain, MD, MBAYasmin Abaza, MDThomas LeBlanc, MD, MAAmer Zeidan, MBBS, MD
Panel of four doctors discussing biomarker testing and safety in HER2-mutated non-small cell lung cancer during Ep. 4 of OncUpdates.

Clinical Insights

07/29/2026

Ep. 4: Biomarker Testing and Safety Considerations in HER2-Mutated NSCLC

Charu Aggarwal, MD, MPHSamuel Caughron, MDPaolo Tarantino, MDRahul Gosain, MD, MBARohit Gosain, MD
Evolving approaches in low-risk myelodysplastic syndromes with expert doctors Dr. Yasmin Abaza, Dr. Thomas LeBlanc, Dr. Hetty Carraway, Dr. Rahul Gosain, and Dr. Amer Zeidan.

Clinical Insights

07/28/2026

The Role of Imetelstat in Lower-Risk Myelodysplastic Syndromes

Hetty Carraway, MDRahul Gosain, MD, MBAYasmin Abaza, MDThomas LeBlanc, MD, MAAmer Zeidan, MBBS, MD

Treatment Algorithms

View All
Promotional image for OncUpdates featuring Dr. Shaji Kumar, Dr. Rohit Gosain, and Dr. Rahul Gosain discussing navigating first relapse in multiple myeloma.

Treatment Algorithm

08/06/2026

Navigating First Relapse in Multiple Myeloma

Shaji Kumar, MDRahul Gosain, MD, MBARohit Gosain, MD
Group of three medical professionals discussing guidelines for systemic therapy during radiation therapy.

Treatment Algorithm

08/02/2026

Guidelines for Continuing or Holding Systemic Therapy During Radiation Therapy

Nina Sanford, MDRahul Gosain, MD, MBARohit Gosain, MD
Three medical professionals, including Dr. Gurbakhash Kaur, Dr. Rohit Gosain, and Dr. Rahul Gosain, discussing treatment algorithms for newly diagnosed and smoldering multiple myeloma in 2026.

Treatment Algorithm

07/29/2026

2026 Treatment Algorithms for Newly Diagnosed and Smoldering Multiple Myeloma

Gurbakhash Kaur, MDRahul Gosain, MD, MBARohit Gosain, MD
Medical professionals discussing treatment options for BRAF V600E-mutated NSCLC, highlighting personalized approaches and targeted therapies for lung cancer patients.

Treatment Algorithm

05/26/2026

How To Select Between Treatment Options for BRAF V600E–Mutated NSCLC

Gregory Riely, MD, PhDRahul Gosain, MD, MBARohit Gosain, MD
Advanced frontline therapy for metastatic NSCLC without actionable mutations.

Treatment Algorithm

05/18/2026

The Frontline Treatment Algorithm for Metastatic NSCLC Without Actionable Mutations

Chirstine Garcia, MD, MPHRahul Gosain, MD, MBARohit Gosain, MD
Dr. Eric Singhi smiling in a professional portrait, with two other doctors discussing targeted therapies for metastatic non-small cell lung cancer (NSCLC) with actionable mutations.

Treatment Algorithm

05/15/2026

Frontline Treatments for Metastatic NSCLC With Actionable Mutations 

Eric Singhi, MDRahul Gosain, MD, MBARohit Gosain, MD
Expert medical team discussing curative treatment options for early-stage non-small cell lung cancer (NSCLC).

Treatment Algorithm

05/11/2026

Standard of Care Curative Treatments for Early-Stage NSCLC

Sanjay Popat, FRCP, PhDRahul Gosain, MD, MBARohit Gosain, MD
Overview of treatment standards for small cell lung cancer (SCLC) across limited- and extensive-stage disease, highlighting current care practices and expert insights.

Treatment Algorithm

05/05/2026

Standard of Care in SCLC: Treatment Across Limited- and Extensive-Stage Disease

Jacob Sands, MDRahul Gosain, MD, MBARohit Gosain, MD

Challenging Cases

View All
Medical conference image featuring Dr. Matthew Lunning, Dr. Gilles Salles, Dr. Rohit Gosain, and Dr. Rahul Gosain discussing challenging DLBCL cases.

Challenging cases

07/30/2026

Challenging DLBCL Cases: Early Relapse and Follicular Lymphoma Transformation

Matthew Lunning, DO, FACPGilles Salles, MD, PhDRahul Gosain, MD, MBARohit Gosain, MD
Three doctors, including Dr. Pedro Barata, Dr. Rohit Gosain, and Dr. Rahul Gosain, are featured in a professional medical setting with a red background, discussing metastatic RCC treatment options.

Challenging cases

07/03/2026

Selecting Frontline and Subsequent Treatment Options for Metastatic RCC

Pedro Barata, MD, MSc, FACPRahul Gosain, MD, MBARohit Gosain, MD
Prominent oncology experts Dr. Shirish Gadgeel, Dr. Wade Iams, Dr. Rohit Gosain, and Dr. Rahul Gosain discuss advanced treatment and management options for mEGFR NSCLC patients.

Challenging cases

06/04/2026

Experts Review Best Practices in Metastatic EGFR–Mutated NSCLC Cases

Shirish Gadgeel, MBBS, FASCOWade Iams, MD, MSCIRahul Gosain, MD, MBARohit Gosain, MD
Prominent oncology experts Dr. Shirish Gadgeel, Dr. Wade Iams, Dr. Rohit Gosain, and Dr. Rahul Gosain discuss advanced treatment and management options for mEGFR NSCLC patients.

Challenging cases

06/04/2026

Doctors Review Best Practices in Metastatic EGFR–Mutated NSCLC Cases

Rohit Gosain, MDRahul Gosain, MD, MBAShirish Gadgeel, MBBS, FASCOWade Iams, MD, MSCI
Experts evaluate targeted therapies for relapsed or refractory AML in challenging cases, featuring Dr. Joshua Zeidner, Dr. Rohit Gosain, and Dr. Rahul Gosain.

Challenging cases

05/27/2026

Experts Evaluate Targeted Therapies in Relapsed or Refractory AML

Joshua Zeidner, MDRahul Gosain, MD, MBARohit Gosain, MD
Dr. Fadi Haddad, Dr. Gabriela Hobbs, Dr. Rohit Gosain, and Dr. Rahul Gosain discuss challenging oncology cases, including frontline TKI for CML and treatment options.

Challenging cases

05/25/2026

Challenging Cases: Frontline TKI for CML and Options Upon Progression

Fadi Haddad, MDGabriela Hobbs, MDRahul Gosain, MD, MBARohit Gosain, MD
Advanced medical professionals discussing evolving treatment options for therapy-related and de novo AML in hematology research.

Challenging cases

02/11/2026

Challenging Cases: The Evolving Treatment Landscape for Therapy-Related and De Novo AML

Naval Daver, MDRahul Gosain, MD, MBARohit Gosain, MD
1. Expert panel discussing diagnosis and treatment of anemia and iron overload in cancer patients at OncUpdates conference.

Challenging cases

12/07/2025

Challenging Cases: Diagnosis and Treatment of Anemia or Iron Overload

Marina Beltrami-Moreira, MDRahul Gosain, MD, MBARohit Gosain, MD

New Approvals

View All
Dr. Sara Tolaney, Dr. Rahul Gosain, and Dr. Rohit Gosain discuss new indications for Sacituzumab Govitecan in TNBC.

New Approvals

07/13/2026

ASCENT-03 and ASCENT-04 Lead to New Indications for Sacituzumab Govitecan in TNBC

Sara Tolaney, MD, MPHRahul Gosain, MD, MBARohit Gosain, MD
Dr. Scott Kopetz discusses a new treatment option for metastatic colorectal cancer with BRAF V600E mutation, featuring experts Dr. Rahul Gosain and Dr. Rohit Gosain.

New Approvals

04/30/2026

BREAKWATER: New Treatment Option for Metastatic Colorectal Cancer With BRAF V600E Mutation

Scott Kopetz, MD, PhDRahul Gosain, MD, MBARohit Gosain, MD
Dr. Luciano Costa, Dr. Rahul Gosain, and Dr. Rohit Gosain discussing approved treatments for relapsed multiple myeloma, highlighting recent advances in oncology research.

New Approvals

03/10/2026

Teclistamab Plus Daratumumab Approved for Relapsed or Refractory Multiple Myeloma After MajesTEC-3

Luciano Costa, MDRahul Gosain, MD, MBARohit Gosain, MD
Expert panel discussing clinical implications of Enfortumab Vedotin plus Pembrolizumab in cisplatin-ineligible metastatic bladder cancer at OncUpdates.

New Approvals

03/03/2026

Transformative Data in Cisplatin-Ineligible MIBC: Clinical Implications of Enfortumab Vedotin Plus Pembrolizumab

Thomas Powles, MD, MBBS, MRCPRahul Gosain, MD, MBARohit Gosain, MD
Expert discussion on IL-15 therapy in cancer care featuring Dr. Patrick Soon-Shiong, Dr. Rahul Gosain, and Dr. Rohit Gosain at OncUpdates.

New Approvals

02/25/2026

The Promise of Anktiva: Expert Insight on IL-15 Therapy in Cancer Care

Patrick Soon-Shiong, MDRahul Gosain, MD, MBARohit Gosain, MD
Quality image showing Dr. Vincent Rajkumar, Dr. Rahul Gosain, and Dr. Rohit Gosain discussing Aquila Trial Insights on Daratumumab for high-risk smoldering myeloma treatment, featured on OncUpdates.

New Approvals

02/21/2026

AQUILA Trial Insights: Daratumumab for the Treatment of High-Risk Smoldering Myeloma

S. Vincent Rajkumar, MDRahul Gosain, MD, MBARohit Gosain, MD
Enhanced breast cancer research presentation featuring Dr. Sara Tolaney, Dr. Rahul Gosain, and Dr. Rohit Gosain discussing T-DXd Plus Pertuzumab and new data in HER2+ metastatic breast cancer.

New Approvals

02/18/2026

T-DXd Plus Pertuzumab and New Data in HER2+ Metastatic Breast Cancer

Sara Tolaney, MD, MPHRohit Gosain, MDRahul Gosain, MD, MBA
EPCORE FL-1 trial discussing Epcoritamab, Lenalidomide, and Rituximab for follicular lymphoma, featuring Dr. Giles Salles, Dr. Rahul Gosain, and Dr. Rohit Gosain, highlighting advancements in lymphoma treatment and research.

New Approvals

12/04/2025

EPCORE FL-1: Epcoritamab Plus Lenalidomide and Rituximab for Follicular Lymphoma

Gilles Salles, MD, PhDRahul Gosain, MD, MBARohit Gosain, MD

Tox Check

View All
Group photo of three doctors discussing CAR T-Cell Therapy in Multiple Myeloma, highlighting collaboration and adverse effects management.

Tox Check

08/04/2026

CAR T-Cell Therapy in Multiple Myeloma: Managing Adverse Effects Through Collaboration

Caitlin Costello, MDJoshua Richter, MDRahul Gosain, MD, MBARohit Gosain, MD
Group photo of three medical professionals discussing BRAF and MEK inhibitor side effects in NSCLC, featuring Dr. Melissa Johnson, Dr. Rohit Gosain, and Dr. Rahul Gosain.

Tox Check

05/28/2026

BRAF and MEK Inhibitor Side Effects in BRAF V600E–Mutated NSCLC

Melissa Johnson, MDRahul Gosain, MD, MBARohit Gosain, MD
Experts discussing targeted therapy strategies for managing toxicities in multiple myeloma treatment, featuring Dr. Hamza Hashmi, Dr. Cesar Rodriguez, Dr. Rohit Gosain, and Dr. Rahul Gosain.

Tox Check

05/20/2026

Bispecific Therapy in Multiple Myeloma: Strategies for Managing Toxicities

Hamza Hashmi, MDCesar Rodriguez, MDRahul Gosain, MD, MBARohit Gosain, MD
Expert discussion on managing side effects of EGFR inhibitors in non-small cell lung cancer (NSCLC) with Dr. Azam Farooqi, Dr. Joshua Sabari, Dr. Rohit Gosain, and Dr. Rahul Gosain.

Tox Check

05/18/2026

How To Manage Side Effects of EGFR Inhibitors in NSCLC

Azam Farooqui, MDJoshua Sabari, MDRahul Gosain, MD, MBARohit Gosain, MD
Expert guidance on managing side effects of colorectal cancer therapies, featuring Dr. Rona Yaeger and colleagues, for improved patient care and treatment outcomes.

Tox Check

05/06/2026

How to Manage Side Effects of Colorectal Cancer Therapies

Rona Yaeger, MDRahul Gosain, MD, MBARohit Gosain, MD
Toxicity check for PI3K/AKT inhibitor side effects in metastatic breast cancer with experts Dr. Emily Gallagher and Dr. Neil Iyengar.

Tox Check

01/06/2026

PI3K/AKT Inhibitor Side Effect Management in Metastatic Breast Cancer

Emily Gallagher, MD, PhDNeil Iyengar, MDRohit Gosain, MDRahul Gosain, MD, MBA
Toxicity awareness in novel antibody-drug conjugates and NSCLC, featuring expert insights from Dr. Jacob Sands, Dr. Rohit Gosain, and Dr. Rahul Gosain on key adverse effects and safety considerations.

Tox Check

01/02/2026

Key Adverse Effects of Novel Antibody-Drug Conjugates in NSCLC

Jacob Sands, MDRahul Gosain, MD, MBARohit Gosain, MD
Optimizing ROS1 inhibitor therapy in NSCLC with insights from Dr. Estelamari Rodriguez and colleagues for cancer research and targeted lung cancer treatment.

Tox Check

11/15/2025

Optimizing ROS1 Inhibitor Therapy in NSCLC

Estelamari Rodriguez, MD, MPHRohit Gosain, MDRahul Gosain, MD, MBA

Resource Centers

View All
Group photo of three doctors discussing CAR T-Cell Therapy in Multiple Myeloma, highlighting collaboration and adverse effects management.

Resource Centers

08/04/2026

CAR T-Cell Therapy in Multiple Myeloma: Managing Adverse Effects Through Collaboration

Caitlin Costello, MDJoshua Richter, MDRahul Gosain, MD, MBARohit Gosain, MD
Panel discussion on treatment options in multiple myeloma featuring Dr. Marco Davila, Dr. Krina Patel, Dr. Rohit Gosain, and Dr. Rahul Gosain at OncUpdates.

Resource Centers

07/27/2026

Myeloma Specialists Discuss Treatment Options in Multiple Myeloma Cases

Marco Davila, MD, PhDKrina Patel, MD, MScRahul Gosain, MD, MBARohit Gosain, MD
Overview of CAR T-cell therapy and bispecific antibodies for relapsed or refractory multiple myeloma with real-world sequencing insights.

Resource Centers

07/14/2026

CAR T or Bispecific Antibodies First? Real-World Sequencing Insights in Relapsed/Refractory Multiple Myeloma

Sawyer Bawek, DO
CAR T-cell therapy in multiple myeloma with insights from ASCO 2026, featuring experts Dr. Binod Dhakal, Dr. Surbhi Sidana, Dr. Rohit Gosain, Dr. Rahul Gosain, and Dr. Ajai Chari.

Resource Centers

06/27/2026

CAR T in Myeloma: Earlier Use and Sequencing Insights from ASCO 2026

Ajai Chari, MDBinod Dhakal, MDSurbhi Sidana, MDRahul Gosain, MD, MBARohit Gosain, MD
Two medical professionals, a woman and a man, in white coats with a city skyline background, discussing RAS-targeted therapy in pancreatic adenocarcinoma.

Resource Centers

06/19/2026

Daraxonrasib and the Future of RAS Inhibitors in Pancreatic Cancer

Antonella Cammarota, PhDMichael May, MD
Panel discussion on managing toxicity and expanding RAS therapy in pancreatic cancer featuring Dr. Andrew H. Ko, Dr. Eileen O'Reilly, Dr. Rohit Gosain, Dr. Rahul Gosain, Dr. Rachna Shroff, and Dr. Shu.

Resource Centers

06/16/2026

Managing Toxicity and Expanding RAS Therapy in Pancreatic Cancer

Andrew H. Ko, MDEileen O'Reilly, MDShubham Pant, MD, MBBSRachna Shroff, MD, MS, FASCORahul Gosain, MD, MBARohit Gosain, MD
Panel of oncology experts discussing the clinical impact of RASolution 302 in doubling patient survival.

Resource Centers

06/15/2026

Doubling Survival: The Clinical Impact of RASolute 302

Andrew H. Ko, MDEileen O'Reilly, MDShubham Pant, MD, MBBSRachna Shroff, MD, MS, FASCORahul Gosain, MD, MBARohit Gosain, MD
Panel discussion on drug development and clinical success in RAS-driven cancer, featuring experts Dr. Andrew H. Ko, Dr. Eileen O'Reilly, Dr. Rohit Gosain, Dr. Rahul Gosain, Dr. Rachna Shroff, and Dr.

Resource Centers

06/14/2026

From Drug Design to Phase 3 Success in RAS-Driven Disease

Andrew H. Ko, MDEileen O'Reilly, MDShubham Pant, MD, MBBSRachna Shroff, MD, MS, FASCORahul Gosain, MD, MBA

Articles

View All
Healthcare professional holding a tray of blood samples at ISTH 2026 conference on cancer-associated thrombosis.

Article

07/30/2026

ISTH 2026: Key Takeaways in Cancer-Associated Thrombosis and Thrombocytopenia 

William Archibald, MDKevin Zablonski, MD
Close-up of a healthcare professional holding a HER2-targeted therapy medication, emphasizing advancements in HER2-directed treatment.

Article

07/23/2026

Trastuzumab Deruxtecan and the Evolution of HER2-Directed Therapy

Jasmin Hundal, MD
Overview of CAR T-cell therapy and bispecific antibodies for relapsed or refractory multiple myeloma with real-world sequencing insights.

Article

07/14/2026

CAR T or Bispecific Antibodies First? Real-World Sequencing Insights in Relapsed/Refractory Multiple Myeloma

Sawyer Bawek, DO
Presentation slide showing SARC041 study on CDK4/6 inhibition as a treatment for dedifferentiated liposarcoma with modern cityscape background.

Article

06/29/2026

SARC041: Establishing CDK4/6 Inhibition as a New Treatment Option in Dedifferentiated Liposarcoma

Samantha Armstrong, MD
Microscopic view of blood cells showing leukemia, highlighting Ziftomenib Plus induction for AML treatment.

Article

06/24/2026

EHA 2026: Ziftomenib Plus Intensive Induction Shows Deep Durable Responses in Newly Diagnosed NPM1-Mutant or KMT2A-Rearranged AML

Sawyer Bawek, DO
City street scene with theater marquee and skyscrapers, highlighting recent advances in GU cancers from ASCO 2026.

Article

06/19/2026

Practice-Changing Shifts in GU Cancers From ASCO 2026

Manas Pustake, MD
Cityscape with river and skyscrapers, highlighting new cancer treatment developments in head and neck cancer research.

Article

06/17/2026

From Resistance to Response: Amivantamab Opens a New Chapter in Head and Neck Cancer

Coral Olazagasti, MD
City skyline with water and text about GU experts on bladder, kidney, and prostate cancer trials.

Article

06/17/2026

GU Experts Weigh In on Trials That Could Redefine Bladder, Kidney, and Prostate Cancer Care

Andre Kydd, MD, PhD

Events

View Events
Clinicals to Exam: Hematology in New Orleans, LA

Clinicals to Exam: Hematology in New Orleans, LA

December 12, 2026

This program, coinciding with ASH 2026 in New Orleans, is designed to equip fellows with essential knowledge and...

Advancements in Oncology: ASH in New Orleans, LA

Advancements in Oncology: ASH in New Orleans, LA

December 12, 2026

Join the Oncology Brothers and leading experts in New Orleans for an exclusive live event exploring how new...

Advancements in Oncology: SABCS in San Antonio, TX

Advancements in Oncology: SABCS in San Antonio, TX

December 8, 2026

Join the Oncology Brothers and leading experts in San Antonio for an exclusive live event exploring how new...

Advancements in Oncology: ASCO GI in San Francisco, CA

Advancements in Oncology: ASCO GI in San Francisco, CA

January 21, 2027

Join the Oncology Brothers and leading experts in San Francisco for an exclusive live event exploring how new...